. Author manuscript; available in PMC: 2011 Aug 1.

Published in final edited form as: Respir Med. 2010 Mar 3;104(8):1189–1196. doi: 10.1016/j.rmed.2009.10.030

Table 2.

All-cause mortality and prevalence of respiratory symptoms, according to GOLD and SR-tile cut-points

A. All-cause mortality:
Spirometric Group	No. (%) of deaths among participants ^*
Normal Pulmonary Function ^†	429/1,488 (28.8)
FEV1/FVC < .70: FEV1 Stage	GOLD Stage 1 ≥ 80%Pred	GOLD Stage 2 50-79%Pred	GOLD Stage 3/4 < 50%Pred	Total
≥ 5^th SR-tile	163/443 (36.8)	90/209 (43.1)	0	253/652 (38.8)
< 5^th SR-tile	0	55/105 (52.4)	56/74 (75.7)	111/179 (62.0)
Total	163/443 (36.8)	145/314 (46.2)	56/74 (75.7)	364/831 (43.8)
B. Respiratory symptoms:^‡
Spirometric Group	No. (%) of participants with respiratory symptoms ^§
Normal Pulmonary Function ^†	614/1,483 (41.4)
FEV1/FVC < .70: FEV1 Stage	GOLD Stage 1 ≥ 80%Pred	GOLD Stage 2 50-79%Pred	GOLD Stage 3/4 < 50%Pred	Total
≥ 10^th SR-tile	172/442 (38.9)	40/77 (52.0)	0	212/519 (40.8)
< 10^th SR-tile	1/1 (100)	141/236 (59.8)	59/74 (79.7)	201/311 (64.6)
Total	173/443 (39.0)	181/313 (57.8)	59/74 (79.7)	413/830 (49.8)

COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; %Pred = percent predicted; SR-tile = standardized residual percentile; GOLD = Global Initiative for Obstructive Lung Disease; LLN = lower limit of normal.

74 participants (3.6%) were excluded because of missing covariates and 87 (3.5%) were excluded because of restrictive pulmonary physiology, i.e., FEV1/FVC ≥ .70 and FVC < LLN.

^†

Defined by an FEV1/FVC ≥ .70 and FVC ≥ LLN.

^‡

Included cough or sputum production, wheezing, or exertional dyspnea - see methods.

^§

80 participants (3.2%) were excluded because of missing covariates or missing respiratory symptoms (n=6), and 87 (3.5%) were excluded because of restrictive pulmonary physiology, i.e., FEV1/FVC ≥ .70 and FVC < LLN.